Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

<p>Topline data results from the STRIDE study are expected in December 2023 IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced last patient last visit (LPLV) in the pivotal STRIDE study […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/reneo-pharmaceuticals-announces-last-patient-last-visit-in-the-pivotal-stride-study-of-mavodelpar-in-primary-mitochondrial-myopathies-pmm/">Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>